Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VERU, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Enobosarm | Metastatic Breast Cancer | Phase 3 · NCT04869943 | Terminated |
| Sabizabulin (VERU-111) | SARS-CoV Infection | Phase 3 · NCT04842747 | Completed |
| Sacituzumab Govitecan | Metastatic Triple Negative Breast Cancer | Phase 2 · NCT05008510 | Withdrawn |
| Semaglutide (Wegovy) weekly injection | Obesity & Overweight | Phase 2 · NCT07446998 | Active not recruiting |
| GnRH Antagonist VERU-100 | Advanced Prostate Adenocarcinoma | Phase 1/2 · NCT04843319 | Terminated |
| Zuclomiphene Citrate | Prostate Cancer Metastatic | Phase 2 · NCT03646162 | Completed |
Also used in these trials (approved or third-party drugs, not VERU's own candidates): Abemaciclib, Enzalutamide, Exemestane, Oral Semaglutide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VERU holds $23.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.2M/quarter from operations, an estimated runway of 10 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 77 · High
Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of these financial statements.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VERU files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Alyeska Investment Group, L.P. | Institution (13G, 5%+) | 1,588,982 | 9.32% | 2025-12-31 |
| Vanguard Capital Management LLC | Institution (13F) | 698,439 | 4.10% | 2026-06-30 |
| Michael L Rankowitz Director · +220,000 options |
Insider | 250,000 | 1.47% | 2025-02-18 |
| Oppenheimer & Co Inc | Institution (13F) | 210,843 | 1.24% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 167,084 | 0.98% | 2026-06-30 |
| Renaissance Technologies, LLC | Institution (13F) | 164,450 | 0.96% | 2026-06-30 |
| GSA Capital Partners LLP | Institution (13F) | 157,336 | 0.92% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 155,076 | 0.91% | 2026-06-30 |
| Summit Financial, LLC | Institution (13F) | 141,865 | 0.83% | 2026-06-30 |
| Jane Street Group, LLC | Institution (13F) | 127,853 | 0.75% | 2026-06-30 |
| FNY Investment Advisers, LLC | Institution (13F) | 105,081 | 0.62% | 2026-06-30 |
| K Gary Barnette Chief Scientific Officer · +291,000 options |
Insider | 2,300 | 0.01% | 2026-08-13 |
Share count 17,050,320 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-13 filed 2026-08-17 |
BARNETTE K GARY |
Purchase (P) | 1,800 | $2.69 | 2,300 |
| 2026-05-04 filed 2026-05-06 |
Greco Michele |
Option award (A) | 164,000 | – | – |
| 2026-05-04 filed 2026-05-06 |
Lu Lucy |
Option award (A) | 104,000 | – | – |
| 2026-05-04 filed 2026-05-06 |
Rankowitz Michael L |
Option award (A) | 100,000 | – | – |
| 2026-05-04 filed 2026-05-06 |
Katzovitz Loren Mark |
Option award (A) | 102,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VERU and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →